Many forms and stages of cancer continue to elude control. Malignant cells adapt and exploit mutations and redundancies, so partial targeting leaves vulnerabilities. Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes.

Team Olema’s work at the bench is focused on addressing the challenges of existing therapies for ER+ breast cancer and generating data to guide the development of next generation therapies.